Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-8448b6f56d-c47g7 Total loading time: 0 Render date: 2024-04-24T19:51:48.660Z Has data issue: false hasContentIssue false

Chapter 22 - A rational approach to employing high plasma levels of antipsychotics for violence associated with schizophrenia: case vignettes

from Section 5 - Psychopharmacology

Published online by Cambridge University Press:  19 October 2021

By
Jonathan M. Meyer
Edited by
Katherine D. Warburton  and
Stephen M. Stahl
Katherine D. Warburton
Affiliation:
University of California, Davis
Stephen M. Stahl
Affiliation:
University of California, San Diego
Get access

Summary

A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Chapter
Information
Violence in Psychiatry , pp. 234 - 242
Publisher: Cambridge University Press
Print publication year: 2016

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Bollini, P, Andreani, A, Colombo, F, et al. High-dose neuroleptics: uncontrolled clinical practice confirms controlled clinical trials. Br. J. Psychiatry. 1984; 144(1): 25–27.Google Scholar
Mackay, AVP. High-dose antipsychotic medication. Advances in Psychiatric Treatment. 1994; 1(1): 16–23.Google Scholar
Krakowski, MI, Kunz, M, Czobor, P, Volavka, J. Long-term high-dose neuroleptic treatment: who gets it and why? Hosp. Community Psychiatry. 1993; 44(7): 640–644.Google Scholar
Frogley, C, Taylor, D, Dickens, G, Picchioni, M. A systematic review of the evidence of clozapine’s anti-aggressive effects. Int. J. Neuropsychopharmacol.. 2012; 15(9): 1351–1371.Google Scholar
Volavka, J, Czobor, P, Nolan, K, et al. Overt aggression and psychotic symptoms in patients with schizophrenia treated with clozapine, olanzapine, risperidone, or haloperidol. J. Clin. Psychopharmacol. 2004; 24(2): 225–228.Google Scholar
Royal College of Psychiatrists. Consensus Statement on High-Dose Antipsychotic Medication. Council Report CR138. London: Royal College of Psychiatrists; 2006.Google Scholar
Paton, C, Barnes, TR, Cavanagh, MR, Taylor, D, Lelliott, P; POMH-UK project team. High-dose and combination antipsychotic prescribing in acute adult wards in the UK: the challenges posed by p.r.n. prescribing. Br. J. Psychiatry. 2008; 192(6): 435–439.CrossRefGoogle Scholar
Meyer, JM. Drug–drug interactions with antipsychotics. CNS Spectr. 2007; 12(Suppl 21): 6–9.CrossRefGoogle ScholarPubMed
Kirchheiner, J, Schmidt, H, Tzvetkov, M, et al. Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication. Pharmacogenomics J. 2007; 7(4): 257–265.CrossRefGoogle ScholarPubMed
Uchida, H, Takeuchi, H, Graff-Guerrero, A, et al. Predicting dopamine D2 receptor occupancy from plasma levels of antipsychotic drugs: a systematic review and pooled analysis. J. Clin. Psychopharmacol. 2011; 31(3): 318–325.Google Scholar
Krakowski, MI, Czobor, P, Citrome, L, Bark, N, Cooper, TB. Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder. Arch. Gen. Psychiatry. 2006; 63(6): 622–629.Google Scholar
Krakowski, MI, Czobor, P, Nolan, KA. Atypical antipsychotics, neurocognitive deficits, and aggression in schizophrenic patients. J. Clin. Psychopharmacol. 2008; 28(5): 485–493.CrossRefGoogle ScholarPubMed
Glick, ID, Balon, RJ, Ballon, J, Rovine, D. Teaching pearls from the lost art of psychopharmacology. J. Psychiatr. Pract. 2009; 15(5): 423–426.Google Scholar
Simpson, GM, Kunz-Bartholini, E. Relationship of individual tolerance, behavior and phenothiazine produced extrapyramidal system disturbance. Dis. Nerv. Syst. 1968; 29(4): 269–274.Google ScholarPubMed
Merck under license to Forest Pharmaceuticals. Saphris [package insert]. St. Louis, MO: Forest Pharmaceuticals, Inc.; 2014.Google Scholar
Sunovion Pharmaceuticals, Inc. Latuda [package insert]. Marlborough, MA: Sunovion Pharmaceuticals, Inc.; 2013.Google Scholar
Haslemo, T, Olsen, K, Lunde, H, Molden, E. Valproic acid significantly lowers serum concentrations of olanzapine – an interaction effect comparable with smoking. Ther. Drug Monit. 2012; 34(5): 512–517.Google Scholar
Longo, LP, Salzman, C. Valproic acid effects on serum concentrations of clozapine and norclozapine. Am. J. Psychiatry. 1995; 152(4): 650.Google ScholarPubMed
Coryell, W, Miller, DD, Perry, PJ. Haloperidol plasma levels and dose optimization. Am. J. Psychiatry. 1998; 155(1): 48–53.CrossRefGoogle ScholarPubMed
Midha, KK, Hubbard, JW, Marder, SR, Marshall, BD, Van Putten, T. Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia. J. Psychiatry. Neurosci. 1994; 19(4): 254–264.Google Scholar
Perry, PJ, Lund, BC, Sanger, T, Beasley, C. Olanzapine plasma concentrations and clinical response: acute phase results of the North American Olanzapine Trial. J. Clin. Psychopharmacol. 2001; 21(1): 14–20.CrossRefGoogle ScholarPubMed
Gefvert, O, Eriksson, B, Persson, P, et al. Pharmacokinetics and D2 receptor occupancy of long-acting injectable risperidone (Risperdal Consta) in patients with schizophrenia. Int. J. Neuropsychopharmacol. 2005; 8(1): 27–36.CrossRefGoogle ScholarPubMed
Mamo, D, Kapur, S, Keshavan, M, et al. D2 receptor occupancy of olanzapine pamoate depot using positron emission tomography: an open-label study in patients with schizophrenia. Neuropsychopharmacology. 2008; 33(2): 298–304.Google Scholar
Seto, K, Dumontet, J, Ensom, MH. Risperidone in schizophrenia: is there a role for therapeutic drug monitoring? Ther Drug Monit. 2011; 33(3): 275–283.Google Scholar
Hiemke, C, Baumann, P, Bergemann, N, et al. AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. Pharmacopsychiatry. 2011; 44(6): 195–235.Google Scholar
Salzman, C, Glick, ID, Keshavan, MS. The 7 sins of psychopharmacology. J. Clin. Psychopharmacol. 2010; 30(6): 653–655.Google Scholar
Kelly, DL, Richardson, CM, Yu, Y, Conley, RR. Plasma concentrations of high-dose olanzapine in a double-blind crossover study. Hum. Psychopharmacol. 2006; 21(6): 393–398.Google Scholar
Meyer, JM. Understanding depot antipsychotics: an illustrated guide to kinetics. CNS Spectr. 2013; 18(Suppl 1): 55–68.CrossRefGoogle ScholarPubMed
Van Putten, T, Marder, SR, Mintz, J, Poland, RE. Haloperidol plasma levels and clinical response: a therapeutic window relationship. Am. J. Psychiatry. 1992; 149(4): 500–505.Google Scholar
Stauffer, V, Case, M, Kollack-Walker, S, et al. Trajectories of response to treatment with atypical antipsychotic medication in patients with schizophrenia pooled from 6 double-blind, randomized clinical trials. Schizophr. Res. 2011; 130(1–3): 11–19.Google Scholar
Wei, FC, Jann, MW, Lin, HN, Piao-Chien, C, Chang, WH. A practical loading dose method for converting schizophrenic patients from oral to depot haloperidol therapy. J. Clin. Psychiatry. 1996; 57(7): 298–302.Google Scholar
Panagiotidis, G, Arthur, HW, Lindh, JD, Dahl, ML, Sjoqvist, F. Depot haloperidol treatment in outpatients with schizophrenia on monotherapy: impact of CYP2D6 polymorphism on pharmacokinetics and treatment outcome. Ther. Drug Monit. 2007; 29(4): 417–422.CrossRefGoogle ScholarPubMed
Kapur, S, Zipursky, R, Roy, P, et al. The relationship between D2 receptor occupancy and plasma levels on low dose oral haloperidol: a PET study. Psychopharmacology (Berl.). 1997; 131(2): 148–152.Google Scholar
Ereshefsky, L, Mascarenas, CA. Comparison of the effects of different routes of antipsychotic administration on pharmacokinetics and pharmacodynamics. J. Clin. Psychiatry. 2003; 64(Suppl 16): 18–23.Google ScholarPubMed
Nyberg, S, Farde, L, Halldin, C, Dahl, ML, Bertilsson, L. D2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate. Am. J. Psychiatry. 1995; 152(2): 173–178.Google Scholar
Levinson, DF, Simpson, GM, Lo, ES, et al. Fluphenazine plasma levels, dosage, efficacy, and side effects. Am. J. Psychiatry. 1995; 152(5): 765–771.Google Scholar
Marder, SR, Midha, KK, Van Putten, T, et al. Plasma levels of fluphenazine in patients receiving fluphenazine decanoate: relationship to clinical response. Br. J. Psychiatry. 1991; 158(5): 658–665.Google Scholar
Ikai, S, Remington, G, Suzuki, T, et al. A cross-sectional study of plasma risperidone levels with risperidone long-acting injectable: implications for dopamine D2 receptor occupancy during maintenance treatment in schizophrenia. J. Clin. Psychiatry. 2012; 73(8): 1147–1152.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×